Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 7:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,947 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Medication Systems Clear all
Withdrawn Phase 1 Interventional Accepts healthy volunteers

VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)

NCT06533280
View directory record Official record
Conditions
HIV Infections
Interventions
Part A, C and D: VH3739937 500 mg, Part A: VH3739937 100 mg, Part A and C: Placebo, Part B: Treatment A, Part B: Treatment B, Part B: Treatment C, Part B: Treatment D, Part B: Treatment E, Part D: Probe cocktail
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Jul 22, 2026, 7:09 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

NCT02502266
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Cediranib, Cediranib Maleate, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Questionnaire Administration, Topotecan, Topotecan Hydrochloride
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
370
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 285 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 22, 2026, 7:09 PM EDT
Terminated Phase 3 Interventional Results available

A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin

NCT02131272
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Insulin detemir, Insulin NPH, Diet/exercise
Drug · Behavioral
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 18 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Jul 22, 2026, 7:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals

NCT00001042
View directory record Official record
Conditions
HIV Infections
Interventions
Aluminum hydroxide, Lipid A, Monophosphoryl, Lipid A, Liposome-encapsulated monophosphoryl, Syntex adjuvant formulation, MF59, Threonyl Muramyl Dipeptide, rgp120/HIV-1 SF-2, MTP-PE/MF59
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1996
U.S. locations
3
States / cities
St Louis, Missouri • Rochester, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 22, 2026, 7:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Developing Rectal USPE Measures for Suppositories (Project DRUM-S)

NCT02744261
View directory record Official record
Conditions
Microbicide Delivery System Perceptibility and Acceptability
Interventions
Gel, Suppository 1, Suppository 2
Other
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jul 22, 2026, 7:09 PM EDT
Completed Phase 1 Interventional Results available

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

NCT04447027
View directory record Official record
Conditions
Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma, Relapsed/ Refractory T-cell Malignancies
Interventions
Romidepsin, Lenalidomide, CC-486 (5-azacitidine), Dexamethasone, EKG, Bone Marrow Aspiration/Biopsy, MRI, Lumbar Puncture, TTE
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jul 22, 2026, 7:09 PM EDT
Completed Not applicable Interventional

An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS

NCT00002142
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Cidofovir, Probenecid
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 7:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Guilford Genomic Medicine Initiative (GGMI)

NCT01372553
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Colon Cancer, Thrombophilia
Interventions
Not listed
Lead sponsor
The Moses H. Cone Memorial Hospital
Other
Eligibility
18 Years and older
Enrollment
1,184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Jul 22, 2026, 7:09 PM EDT
Completed Not applicable Interventional Results available

Improving Treatment and Retention Adherence in Nontraditional Settings

NCT04973254
View directory record Official record
Conditions
HIV Infections
Interventions
CAB-RPV LA, Standard treatment within an HIV clinic
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Jul 22, 2026, 7:09 PM EDT
Completed No phase listed Observational

Bladder Antimuscarinic Medication and Accidental Bowel Leakage

NCT03543566
View directory record Official record
Conditions
Urinary Incontinence, Urge, Fecal Incontinence
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Jul 22, 2026, 7:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD)

NCT01730170
View directory record Official record
Conditions
Epilepsy, Pregnancy
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
14 Years to 45 Years · Female only
Enrollment
565 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2022
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Jul 22, 2026, 7:09 PM EDT
Completed Not applicable Interventional

A Study of Two Anti-HIV Drug Combinations

NCT00002203
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, Lamivudine, Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Beverly Hills, California • Los Angeles, California • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 7:09 PM EDT
Completed Phase 2 Interventional Results available

A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study

NCT00947856
View directory record Official record
Conditions
Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
Interventions
brentuximab vedotin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
6 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
16
States / cities
Birmingham, Alabama • Duarte, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Jul 22, 2026, 7:09 PM EDT
Completed Phase 4 Interventional

Treatment of Obsessive-Compulsive Disorder

NCT00000373
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
olanzapine + fluoxetine, placebo + fluoxetine
Drug
Lead sponsor
University of Florida
Other
Eligibility
14 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2003
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Jul 22, 2026, 7:09 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

NCT03197766
View directory record Official record
Conditions
Achondroplasia
Interventions
BMN 111, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
5 Years to 18 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Oakland, California • Torrance, California • Wilmington, Delaware + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Jul 22, 2026, 7:09 PM EDT
Not listed Phase 3 Interventional

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

NCT00045968
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioblastoma, GBM, Grade IV Astrocytoma, Glioma, Brain Cancer, Brain Tumor
Interventions
Dendritic cell immunotherapy
Drug
Lead sponsor
Northwest Biotherapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
71
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Castro Valley, California + 56 more
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Jul 22, 2026, 7:09 PM EDT
Completed Not applicable Interventional

The Potential of a Low Glutamate Diet as a Treatment for Pediatric Epilepsy

NCT04545346
View directory record Official record
Conditions
Epilepsy in Children, Epilepsy in Youth, Randomized Controlled Trial, Refractory Epilepsy, Diet Intervention
Interventions
Low Glutamate diet
Other
Lead sponsor
American University
Other
Eligibility
2 Years to 21 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Jul 22, 2026, 7:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effect of Talampanel (an AMPA Receptor Blocker) on Brain Activity

NCT00057460
View directory record Official record
Conditions
Healthy
Interventions
Talampanel
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 7:09 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Cultured Circulating Tumor Cells in Prostate and Other Cancers

NCT02123862
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Oscar Goodman, Jr.
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 18, 2015 · Synced Jul 22, 2026, 7:09 PM EDT
Completed Not applicable Interventional

A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease

NCT00000662
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 12 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2016 · Synced Jul 22, 2026, 7:09 PM EDT
Completed Not applicable Interventional

A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use

NCT01669473
View directory record Official record
Conditions
Diabetes Mellitus Type I, Diabetes Mellitus Type II
Interventions
EHR Based Strategy to promote Safe and Appropriate Drug Use
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 90 Years
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Jul 22, 2026, 7:09 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of Methadone

NCT00000788
View directory record Official record
Conditions
Candidiasis, HIV Infections
Interventions
Methadone hydrochloride, Fluconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jul 22, 2026, 7:09 PM EDT
Completed Phase 1 Interventional

A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease

NCT00000696
View directory record Official record
Conditions
HIV Infections
Interventions
Interferon alfa-2a, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
6
States / cities
Los Angeles, California • Miami, Florida • New Orleans, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Jul 22, 2026, 7:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Formative Study to Explore the Sensory Perceptions of Vaginal Product Users

NCT01334827
View directory record Official record
Conditions
Microbicide Delivery System Acceptability
Interventions
high volume gel, low volume gel, vaginal film
Other
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 22, 2026, 7:09 PM EDT